Central Nervous System Schizophrenia

Table of Contents

RECENT HIGHLIGHTS AND CHANGES
--Recent Highlights and Changes
UPCOMING PATENT EXPIRES BY THERAPY AREA
Schizophrenia Pipeline Overview
--% of Projects (By Phase of Development)
--No. of Projects by Phase of Development
--Marketed Products Vs. Pipeline Products
Company Overview - Pipeline Projects
--Company Overview - Pipeline Projects

--Top Companies in late stage Schizophrenia Projects
--ACADIA Pharmaceuticals Inc
--Abbott Laboratories
--BioLineRx, Ltd.
--Barr Pharmaceuticals Inc
--Eli Lilly & Co
--Dainippon Sumitomo Pharma Co., Ltd.
--Fabre-Kramer Pharmaceuticals, Inc.
--Evotec AG
--GlaxoSmithKline plc
--Forest Laboratories Inc
--Laboratorios Almirall, S.A.
--Johnson & Johnson
--Mylan, Inc.
--Merck & Co Inc
--Ranbaxy Laboratories Ltd.
--Potomac Pharma, Inc.
--Solvay S.A.
--Schering-Plough Corp
--Wyeth
--Stem Cell Therapeutics Corp.

--Top Companies in early stage Schizophrenia Projects
--Addex Pharmaceuticals SA
--Abbott Laboratories
--AstraZeneca Plc
--Argolyn Bioscience Inc.
--GlaxoSmithKline plc
--elbion NV
--Johnson & Johnson
--Intra-Cellular Therapies, Inc.
--
--NeuroSearch A/S
--Merck & Co Inc
--Pfizer Inc
--Oakwood Laboratories, L.L.C.
--Roche Holdings Ltd
--Pierre Fabre Medicament
--Sanofi-Aventis
--Rottapharm SpA
--Taisho Pharmaceutical Co., Ltd.
--Sigma-Tau S.p.A.
--Wyeth
--Targacept Inc

Pipeline Revenue
--Pipeline Revenue
Full Pipeline View
--Pre Clinical Pipeline View
--Phase I Pipeline View
--Phase II Pipeline View
--Phase III Pipeline View
--Pending Approval Pipeline View
--Post Marketing Pipeline View
--On the Market Pipeline View
--Discovery/Development Pipeline View